TR201611685A1 - ORAL PHARMACEUTICAL COMPOSITIONS - Google Patents

Abstract

The present invention includes; lung diseases such as colds, chronic obstructive pulmonary disease (COPD), emphysema and bronchospasm, cough, expectoration, otitis media, chronic asthma, chronic bronchitis, bronchial asthma, and / or symptomatic and / or symptomatic suitable active ingredient and / or pharmaceutically acceptable derivatives of the mucolytic nature and / or pharmaceutically acceptable derivatives thereof for use in the therapeutic treatment, and suitable sympathomimetic active ingredient and / or pharmaceutically acceptable derivatives thereof. refers to a pharmaceutical composition (s) comprising combined therapy.

Description

DESCRIPTION ORAL PHARMACEUTICAL COMPOSITIONS FIELD OF THE INVENTION The present invention; colds, chronic obstructive pulmonary disease (COPD), emphysema and lung diseases such as bronchospasm, Cough, expectoration, middle ear inflammation, chronic respiratory system such as chronic asthma, chronic bronchitis, bronchial asthma, bronchiectasis To be used in the prophylactic and/or symptomatic and/or therapeutic treatment of Suitable active substance with mucolytic properties and/or pharmaceutically acceptable derivatives, suitable active substance with analgesic and/or antipyretic properties and/or pharmaceutically acceptable derivatives and suitable agent with sympathomimetic properties substance and/or pharmaceutically acceptable derivatives relates to pharmaceutical composition(s).

The present invention shows that the suitable active substance with mucolytic properties is Ambroxol, trans-4-(2-Amino- 3,5-dibromobenzylamino)-cyclohexanol (Formula 1) and/or pharmaceutically acceptable possible derivatives; of the appropriate active substance with analgesic and/or antipyretic properties. Paracetamol, N-(4-hydroxyphenyl)acetamide (Formula II) and/or pharmaceutically acceptable possible derivatives; Pseudoephedrine, (+)- (1S,ZS)-2-methylamino-1-phenyl-propan-1-ol (Formula III) and/or pharmaceutically acceptable as active ingredients in suitable pharmaceutical forms. relates to the pharmaceutical composition(s) for which it is used in combination.

Formula I: Formula 11: Formula III: In addition, the invention includes Ambroxol and/or pharmaceutically acceptable derivatives, Paracetamol and/or pharmaceutically acceptable derivatives and Pseudoephedrine and/or used in combination with pharmaceutically acceptable derivatives formulations and uses of the compounds suitable for oral administration. covers. PRIOR ART (KNOWN STATE OF THE ART) Chronic Obstructive Pulmonary Disease (COPD) consists of chronic bronchitis and emphysema. leading to progressive dyspnea characterized by obstruction of the incoming airways It is a chronic respiratory disease.

Obstructive lung diseases are common all over the world and are the most important cause of mortality. is one of the reasons. According to the statistics of the World Health Organization, 600 million He has COPD. It is estimated that there are about 3 million people with COPD in our country.

Regardless of the disease causing the obstruction, the obstruction can be seen in the following three It comes with one of the mechanisms: a) Due to pathological events in the lumen b) Due to pathological events that occur in the walls of the respiratory tract c) Due to pathological events around the bronchi Type A chronic obstructive pulmonary diseases (Emphysema type) and type B chronic obstructive There are two main types of COPD, lung diseases (Bronchitis) type.

Chronic Bronchitis is caused by chronic inflammation and thickening of the bronchial walls, It is a disease that progresses with excessive mucus production in the bronchial tree. The weather in this disease The degree of narrowing of the passageways may be enough to impair breathing and coughing frequently. result in crises. The symptoms of patients with chronic bronchitis are cough and excessive expectoration of mucus from inflammation. excessive in practice most days for at least two years and at least three months of two years is an expectation. In chronic bronchitis pathology, the structural feature is the most important. hypertrophy of mucous glands in the bronchi and chronic inflammatory disease in the small airways the presence of changes. Chronic bronchitis is more serious and more frequent respiratory infections, narrowing and blockage of the bronchi, difficulty breathing or can cause weakness.

If emphysema; one of the most common chronic lung diseases leading to respiratory failure is one. A condition that occurs when the air sacs (alveoli) in the lungs are stretched and enlarged. is a disease. This expansion causes the air to rupture the thin walls that separate the vesicles from each other. and therefore causes loss of flexibility in the lungs. As a result, air entry into the lungs and The balance of blood gases (oxygen-carbon dioxide) in the air sacs is disturbed. Advanced In emphysema cases, the lungs are enlarged, withered, and dried. Their flexibility They are like a pillow because there is no left over. When the rib cage is opened, the lungs do not deflate, because air remains in them due to loss of elasticity. The predominant symptom in patients with emphysema short breaths.

Drugs that affect mucus are mucolytics, mucokinetics (expectors) and It can be grouped into 3 classes as mucoregulators.

- Mucolytics break down mucoproteins in mucus, thereby reducing the viscosity of sputum. are drugs that can make it liquid by reducing it. The main ones are; N-acetylcysteine (NAC) and S- is carboxymethyl cysteine (carbocysteine). N-acetylcysteine is a glutathione precursor. It also benefits from the inhibitory effect of free radicals.

° Mucokinetics (expectors) increase mucus flow to expel sputum with coughing makes it easy to throw. The most known drugs of this group are; iodides, glyceryl guajacolate and is bromexin.

- Mucoregulators impair the synthesis of sialomucin, reducing viscosity and secretion. increases. Scarbocysteine is the most widely used in Europe. These drugs are oral or parenteral. given via.

Pharmacological and non-pharmacological treatment of moderate to severe COPD therapies are used. In the study by Cazzola et al. (Respiratory Medicine, V:4, p.8-25, 2008) among pharmacological treatment methods antibiotics, bronchodilators, corticosteroids and mucolytic agents.

Acetaminophen or commonly known as paracetamol, paraaminophenol derivative It is an analgesic and antipyretic drug. When paracetamol is taken orally, gastrointestinal is rapidly absorbed in the system. Maximal plasma 30-60 minutes after drug administration reaches their concentration. Paracetamol is rapidly distributed to all tissues. gastrointestinal almost no side effects in the system, its reliability and Its use ensures that paracetamol is always in the foreground and that it is a classic analgesic. lets it be.

Pseudoephedrine HCl is the stereoisomer of ephedrine; natural in Ephedra-type plants such as ephedrine available as. As medicine, synthetically produced racemic and dextro forms are used. Ephedrine It shows both direct and indirect seinpatoiniinetic activity. Pseudoephedrine (1 and B A clinical picture that stimulates both adrenergic receptors and is associated with both types of effects. It is a drug that has use.

Pseudoephedrine is partly under its peripheral influence for the release of norepinephrine. However, it also has a direct effect on receptors.

Pseudoephedrine is a sympathomimetic amine agent and a potent upper respiratory tract agent. it is decongestant. On the blood vessels in the nose to relieve nasal congestion It is in the group called vasoconstrictors. nasal mucosa It reduces nasal discharge and congestion along with vasoconstriction.

upper respiratory tract allergy or nasal cold associated with pseudoephedrine as a decongestant for temporary relief of nasal congestion, sinus congestion and temporary relief of pressure and symptomatic treatment of otic baro-trauma, or There are areas of use such as prevention.

In the patent document numbered EP2012765, such as colds, flu, allergies, sinusitis and rhinitis Liquid compositions used in the treatment of respiratory tract diseases are mentioned.

These liquid compositions have a certain pH value and contain phenylephrine and acetaminophen.

For use in respiratory tract diseases in the patent document USSI75152 A pharmaceutical formulation containing ephedrine is mentioned.

In the content of the tablet formulation in the patent document numbered USZO14037727; paracetamol an excipient used in the upper respiratory tract and another analgesic. formulations containing

DESCRIPTION OF THE INVENTION The present invention; common cold, chronic obstructive pulmonary disease (COPD), emphysema and lung diseases such as bronchospasm, cough, expectoration, middle ear inflammation, chronic respiratory system such as chronic asthma, chronic bronchitis, bronchial asthma, bronchiectasis To be used in the prophylactic and/or symptomatic and/or therapeutic treatment of Suitable active substance with mucolytic properties and/or pharmaceutically acceptable derivatives, suitable active substance with analgesic and/or antipyretic properties and/or pharmaceutically acceptable derivatives and suitable agent with sympathomimetic properties substance and/or pharmaceutically acceptable derivatives relates to pharmaceutical composition(s).

Another aspect of the present invention is; suitable agent with mucolytic properties for oral use substance and/or pharmaceutically acceptable derivatives, analgesic and/or antipyretic appropriate active ingredient and/or pharmaceutically acceptable derivatives, and Appropriate active substance with sympathomimetic properties and/or pharmaceutically acceptable combination therapy with its derivatives and suitable pharmaceutically acceptable adjuvant relates to the preparation of pharmaceutical composition(s) containing substances.

The appropriate active substance with mucolytic properties used in the invention is not limited to these. together, erdosteine, acetylcysteine, ambroxol, bromhexine, carbocysteine, domiodol, as eprazinone, letosteiii, neltenexin, sobrerol, stepronin, thiopronin and/or pharmaceutically it is preferably selected as ainbroxol hydrochloride from among its acceptable derivatives.

Appropriate active substance with analgesic and/or antipyretic properties used in the invention acetylsalicylic acid, aloxiprine, choline salicylate, sodium salicylate, salicyl salsalate, ethenzamide, morpholine salicylate, dipyrocetyl, benorilate, diflunisal, potassium salicylate, guacetisal, carbasalate calcium, imidazole salicylate, phenazone, metamizole, aminophenazone, propyphenazone, niphenazone, paracetamol, phenacetin, busetin, propacetamol, rimazolium, glafenin, floctafenin, viminol, nefopam, flupirtine, ziconotide, inetoxyflurane, nabiximols, morphine, opium, hydromorphone, nicomorphine, oxycodone, dihydrocodeine, diamorphine, papaveretum, ketobemidon, pethidine, fentanyl, dextromoramide, pyrithramide, dextropropoxypheii, bezitramide, peitazosin, feylazosin, buprenorphine, butorphanol, nalbuphine, tilidine, tramadol, dezosiii, meptazinol, tapentadol, dihydroergotamine, ergotamine, inetisergid, lisuride, ilumedroxone, suinatriptan, naratriptan, zolmitriptan, rizatriptan, almotriptan, eletriptan, frovatriptan, pizotifen, clonidine, iprazochrome, dimethothiazine, oxetorone, preferably among zucapsaicin and/or pharmaceutically acceptable derivatives selected as paracetamol.

The appropriate active substance with sympathomimetic properties used in the invention is limited to these. phenylpropanolamine, pseudoephedrine, phenylephrine, phenylpropylamine and/or among its pharmaceutically acceptable derivatives, preferably pseudoephedrine hydrochloride is selected as.

In the invention, the term "pharmaceutically acceptable derivatives" is defined as pharmaceutically acceptable. Suitable salts, esters, solvates, hydrates, complexes, polymorphs, enantiomers, prodrugs, acid addition salts, analogs, isomers, racemates, amides, enantiomer salts, basic salts, conjugates, tautomers, anhydrates, anhydrides, bases, one or more of acids, ethers, crystalline and amorphous forms or free forms is expressed.

The pharmaceutical composition for oral administration may be in solid or liquid dosage forms.

These dosage forms are; tablet (uncoated, chewable, mouth soluble, dispersible, water dispersible, film coated, single layer, double layer, intestinal release coated, mini tablet, controlled release, sustained release, immediate release, extended release, delayed release release, modified release, buccal), capsule (hard, soft, enteric-coated, film-coated, controlled release, sustained release, immediate release, extended release, delayed release, modified release), powder, dry powder, granule, caplet, disc, mouth soluble film, bulk powder (multi-dose), pellet, sachet, water-dispersible powder, water-dispersible granule, effervescent tablet, effervescent granule, effervescent powder, microcapsule, dental tablets, pilula, syrup, solution, as a dosage form such as suspension, elixir, drops, position, emulsion, or spray. can be formulated.

The finished product is obtained by mixing the active substance and auxiliary substances in powder form. chassis can be formulated as Some of the granules prepared for oral administration are swallowed, some are chewed, some are used by dissolving or dispersing in water or other suitable liquid.

Granules contain one or more active ingredients, excipients, color and fragrance if necessary. They also contain donor substances. They can also be prepared without any excipients. Granules single They can be packaged in dose or multidose form. Multi-dose preparations, at the desired dose They are packaged with a suitable scale so that they can be taken. Single dose granules bag, paper supplied in single-unit containers such as packs or Ilakon. production, packaging, storage and their distribution should be carried out away from microbial contamination. volatile or Granules containing substances to be protected should be stored in tightly closed containers.

Effervescent granules.' They are uncoated granules. Usually acid substances, carbonates or containing bicarbonates and reacting rapidly with water to release carbon dioxide are granules. It is dissolved or dispersed in water before application. As an active substance carrier they are used. In its formulations, it is mixed with acidic substances such as citric acid, tartaric acid, Iimaric acid. they contain alkaline substances such as sodium carbonate, sodium bicarbonate and sodium biphosphate.

Coated granules.' They are mostly multi-dose preparations and contain various excipients. It consists of granules coated in one or more layers with their mixture. Coater Substances used as solvents are often in the form of solutions or suspensions and It is applied in conditions where it is evaporated. Appropriate release of the active substance to the coated granules. A suitable dissolution test, for example, for solid dosage forms one of the tests described can be applied.

Modified release granules.' The release rate, location, or location of the active substance or substances. Containing special excipients or specially designed to modify the timing They are coated or uncoated granules, individually or together, prepared by processes.

A suitable dissolution on these granules to show the mode of release of the active substance. test is applied.

Gastro-resistant granules.' stable in gastric juice and Delayed, designed for the release of the active substance(s) in an intestinal fluid releasing granules. These properties are due to the fact that the granules are combined with a gastric fluid-resistant material. It is provided by coating (enteric coated granules) or by other suitable means. This an appropriate test on the granules to determine the appropriate release of the active substance. For example, one of the tests described for solid dosage forms can be applied.

Many techniques are used in the preparation of dosage forms. one of them granulation method. Granulation; as the growth of fine dust particles is defined. Granulation for pharmaceutical purposes; a preparation for tableting This is the stage of filling hard gelatin capsules or granules as a final product. It is also applied for the purpose of being placed in a package.

The purpose of the granulation is to give the unit drug % of the particles of the powder substance participating in the mixture. is to create a unit of weight that will be equivalent to the quantities. Pharmaceutical powder mixes (active substance or auxiliary substances) in a unit by preventing their separation. It is necessary to ensure that they remain in a homogeneous form, this is achieved by granulation. possible.

The methods to be chosen in granulation can be classified in 3 main categories: wet granulation, dry granulation and other granulation methods.

Age Granulation: In the wet granulation method, high speed fluidized bed granulation, spray drying and extrusion pelletizing methods are used. Mourning In granulation, the active ingredient and the binder (solution) are mixed for a certain period of time. sieved and dried in a fluidized bed dryer. This dried mixture is the other filling. It is mixed with the ingredients until it reaches a certain homogeneity. My wife's last 3-5 slider is added in minutes. Samples are taken from the final mixture obtained and sent to the laboratory. sent. According to the laboratory result, for tablet compression or for the desired pharmaceutical form stages can be passed.

Age granulation methods: 1. Age granulation method (Classical method) 2. Granulation by fluidized bed method 3. Granulation by Spray-Drying method 4. Microgranulation method . Extrusion-Spheronization method 6. Method of preparing granules with high-level mixers The wet granulation process is as follows: - Grinding the active ingredient (if necessary), - Mixing with powder substances, The process is called granulation.) - Screening of agglomerated particles as wet, ° Drying of the sifted powder mixture is widely used in the drying process. using bed dryers, - Adding lubricant to this resulting mixture and mixing for another 5 minutes, (This the mixture is called the final product.) - It is the transition to tablet printing or the stages for the desired pharmaceutical form.

Dry Granulation: In the dry granulation method, pre-compression and inter-roll compression methods are used. In dry granulation, it is usually 1/3 of the lubricant is mixed with other powder mixtures. This is because dust gets into the cylinders. prevents it from sticking. The remainder of the lubricant is added to the mix after dry granulation. and stirred for 3-5 minutes. Samples are taken from the final mixture formed after the mixture and It is sent to the laboratory for various tests. According to the laboratory results, tablet compression or Appropriate steps can be passed for the desired pharmaceutical forin.

Tablet(s) for oral use may contain one or more coatings.

coated tablets; The active ingredient is usually in the core, partially in the core and It is prepared in the form of formulas containing partially coating or only coating.

Coating materials must be physiologically harmless and incompatible with the active substance. should not be.

Coating types ; sugar coating, film coating and intestinal soluble (enteric) coating can be counted as

Sugar-coated tablets are compressed tablets having a coating consisting of sugar. are tablets. The coating may be colored and may have an offensive taste or coating of active substances with odor and sensitive to oxidation It is extremely useful in terms of protecting materials.

Film-coated tablets are a thin film applied using a water-soluble material. Compressed tablets coated with a layer or film. In line with this, the movie Maker A range of polymeric materials can be used with properties Film coatings, sugar Although it has the same general properties as the coatings, it is necessary for the coating process. It brings with it the important additional advantage of significantly reducing the time.

Purposes of Coating; ° Masking off the offending odor and taste of the active ingredient ° Correction of the aesthetic appearance of the tablet ° Obtaining colored tablets with very little dyestuff ° Increasing the easy swallowing of the tablet by the patient ° Increased mechanical strength during production, packaging and transportation ° Protection of the active substance against digestive secretions ° Facilitating the identification of the drug, thus ensuring safety in drug use. increase ° It can be counted as being able to regulate the controlled release characteristics.

The pharmaceutical formulation(s) of the invention may contain one or more layers. Sufficient To ensure the therapeutic effect and to minimize the side effects, the release of the drug should be reduced. layer/s are changed, modified, controlled, extended, continuous, with one or more of the immediate or delayed release pharmaceutical dosage forms can be formulated.

Its pharmacokinetic properties are not suitable for use expectations, eg half-life Short-lived, rapid/high peak with undesirable effects concentration, which is not well bioavailable for various reasons, etc. for drugs by changing their pharmaceutical form, their release patterns in the gastrointestinal tract are aimed for the purpose. More optimized preparations are being developed. These have been changed many times, They are referred to as controlled, slowed and extended release formulations.

The compositions of modified release formulations are important for their function.

Modified-release drug formulations, although they may be more expensive, short half-life, peak, in which adherence to treatment is important for treatment success For drugs that reach concentration rapidly, with varying pharmacokinetics, They are useful and ultimately reduce the cost of treatment. Modified release systems They are classified as transdemial systems and oral systems. delayed release In systems, the release of the active substance from the system occurs in a certain region. Generally It is used for enteric coated tablets.

To increase the stability of the enteric coating formulation, to prevent acid-induced degradation. It is expressed as the substance or substance mixture used for These enteric coatings before it starts to decompose, it resists stomach acid and at the same time, it It provides a slow drug release in the upper part of the small intestine or in the upper part of the small intestine.

capsules; gelatin, cellulose esters, polyvinyl alcohol, etc. for single-dose drug administration. They are containers made of one of the materials. Doses, solid and partial substances into capsules, Liquid drugs that do not dissolve the capsule can be placed. Capsules are generally divided into two; rigid/two-piece capsules and soft capsules.

Hard capsules: consists of two parts, the container and the lid part. Bitter taste, swallowed capsules of difficult, air-perishable powders and drugs that are required to be rapidly absorbed. is anticipated to be given. The main ingredient of hard gelatin capsules is a macromolecular It consists of high-value gelatin, which is a protein. Hard gelatin capsules gelatin, gum arabic, It is prepared from a mixture of paint and water with special techniques and special machines. hard capsules It is prepared by the dipping method. The principle of this method is made of stainless steel on the surface of these rods by dipping them in the melted capsule wall solution. is the formation of the capsule wall film. Gelatin, dyes, preservatives and water, hard They are the substances that make up the gelatin capsule wall.

Hard capsules can be filled in powder, granule, pellet, tablet, liquid, and semi-solid forms.

There are two basic requirements for any formulation filled into capsules. The formulation must be filled in the correct dose and the active substance is released from the capsule for the treatment of the patient. should be released in sufficient quantity. For the preparation of hard gelatin capsule formulations active ingredient, fillers, flow-improving agents, glidants, anti-friction inhibitors, lubricants, dispersants, surfactants are used.

Soft capsules: single gelatin prepared with mixtures of glycerin, sorbitol, gum arabic and water. They are round, elliptical and tube-shaped capsules consisting of pieces. Required items After being placed, they are closed to not open. Soft capsules, gelatin of a liquid content It is prepared by enclosing it with the capsule wall. They are more flexible than hard capsules.

Soft capsules are round, oval, oblong (oblong stick) or tubular they may be. They consist of one piece. Soft gelatin capsules are usually included in solution or Liquid drug forms in suspension form are filled. However, semi-solids and powders are also can be filled. Production of soft capsules, insoluble substances, low-dose active substances, highly active compounds, oxygen sensitive substances, bad taste suitable for materials. In the production of soft gelatin capsules, the capsule wall a successive sequence of preparation, filling of the material and closure of the capsule. consists of the name.

Syrups are active in high skin solutions of sucrose or other sugars. liquid medicine formed by the dissolution of substances and auxiliary substances by various methods are shapes. Syrups prepared by dissolving only 64% sucrose in water It is called Simple Surup (Sirupus Simplex). Syrups contain 85% w/v sugar according to USP 24.

In addition to sugar and other sweeteners, it is added to syrups to prevent crystallization, increase solubility. and adding sorbitol or glycerin to alter the taste and aromatic substances to impart flavor Preparation methods of syrups: - Prepared by simple thawing in hot or cold - Syrups prepared with extracts and tinctures - Prepared by maceration and digestion method - Syrups prepared with fruit juices - Prepared by percolation - Resolution method can be listed as those prepared with.

The pharmaceutical formulation of the present invention for oral use; pharmaceutically Acceptable suitable active ingredients as well as binder, dispersant, filler agent, buffering agent, surfactant, lubricant, glidant, diluent, preservative, flavoring agent, sweetening ingredient, viscosity increasing agent, antifoam agent, solubilizing agent, antistatic agent, wetting agent, pH adjusting agent, coloring agent, coating agent, solvent, softening agent, emulsifier, carrier, permeabilizing agent, antioxidant, chelating agent, alkalizing agent, photoprotective agent, thickening agent, isotonia adjusting agent, gelling agent, antimicrobial preservative substance, curing agent, sivag, release controlling agent, plasticizer, antiadherent, film Builder agent, opacifying agent, wetting agent, granulation solvent, suspension one or more excipients selected from the group including the agent and stabilizer Defines a composition that can contain

The term "binding agent" in the invention; Keep the ingredients together, tablets, pellets or ensuring that the granules are formulated with the required mechanical strength and low active dosage. expressed as substances or mixtures of substances used to give volume to units of is being done. As a binding agent; pregelatinized corn starch, pregelatinized starch, hydroxypropyl starch, gelatin, microcrystalline cellulose, cellulose, gums, polyvinyl pyrrolidone, polymethacrylates, sodium carboxymethyl cellulose, starch, paraffins, stearic acid, gums, methyl cellulose, ethyl cellulose, polyethyleneglycol, magnesium aluminum silicate, carboxy methylcellulose, hydroxy propylcellulose, hydroxy ethylcellulose, propylene glycol, polyoxyethylene- polypropylene copolymer, polyethylene ester, polyethylene sorbitan ester, polyethylene oxide, polysaccharides, polaxamers, alginic acids, collagen, albumin, crospovidone, povidone, Copovidone, maltodextrin, hypromellose or mixtures of these can be used.

In the invention, the term "dispersant" means that the dosage form can be easily and quickly dissolved in water. It is expressed as substances that allow it to disperse. As a dispersant; agar agar, calcium carbonate, sodium carbonate, alginic acid, potato starch, corn starch, wheat Starches such as starch, pregelatinized starch, sodium starch glycolate, inocrystalline cellulose, cross-linked polyvinyl pyrrolidone, sodium alginate, hydroxypropyl cellulose, cross bound hydroxypropyl cellulose, croscarmellose sodium, clay, ion exchange resin, crospovidone, xylitol, D-sorbitol, D-mannitol, lactose, sucrose, urea, high molecular weight polyiners, povidone, alginic acid, xanthan gum, colloidal silicon dioxide or their mixes can be used.

The term "filler" in the invention; practical, patient for the production of tablets or capsules as a substance or a mixture of substances used to be in a suitable size for its use is expressed. As a filler; talc, lactose, sucrose, dextrin, mannitol, lactilol, lactitol, xylitol, sorbitol, isomalt, microcrystalline cellulose, powdered cellulose, dextrose, dextrate, pregelatinized starch, modified starch, corn starch, lactose anhydrous, lactose monohydrate, dibasic calcium phosphate, silicic acid, kaolin, hydroxy propyl methylcellulose, tribasic calcium phosphate, polyhydric alcohols or cellulose ethers, calcium hydrogen phosphate dihydrate, calcium sulfate trihydrate, cellulose calcium sulfate, calcium sulfate dihydrate, maltodextrin, calcium carbonate, kaolin, sodium hydroxide or their mixtures can be used.

In the invention, the term "buffering agent" is used to regulate the acidity and basicity of the composition. referred to as items. As a buffering agent; citric acid anhydrous, sodium citrate dihydrate, sodium phosphate, sodium dihydrogen phosphate, potassium citrate, phosphoric acid, ammonium hydroxide, citric acid, diisopropanolamine, sodium carbonate, sodium silicate, disodium orthophosphate, calcium carbonate, magnesium carbonate, magnesium hydroxide, magnesium aluminate, diethanol amine, sodium alginate, ethylenediamine, meglumine, hydrochloric acid, lactic acid, sodium citrate, sodium hydroxide, triethanoline, trolamine, sodium benzoate, sodium hydrogen carbonate or their mixtures can be used.

In the invention, the term "surfactant" is applied when dissolved in water or an aqueous solution. It refers to the chemical compound that affects its tension. As a surfactant polysorbates, sodiumlauryl sulfate, sodium stearyl fumarate, non-ionic polyoxyethylene polyoxypropylene co-polymer, hexadecyl trimethyl ammonium bromide, alkyl polyethylene oxide, poloxamers, octyl glucoside, sugar esters and glycerides of fatty acids, dodecyl betaine, dodecyl diethylainin oxide, polyoxyl stearate, sodium stearate, polyethylene glycols, L-leucine, alkyl benzene sulfonate, fatty acids, quaternary ammonium compounds or mixtures thereof can be used.

"Lubricant" in the invention is the flow of a powder mixture that reduces or inhibits friction. It is expressed as agent or agent mixtures that improve its properties. lubricant aspect; talc, calcium stearate, magnesium stearate, aluminum stearate, polyethylene glycol, tristearin, stearic acid, sodium lauryl sulfate, magnesium lauryl sulfate, colloidal silicon dioxide, stearic acid, sodium stearyl fumarate, polyoxyethylene glycol, oleic acid, tripalinityl, potassium oleate, hydrogenated vegetable oils, leucine, alanine, glycine, caprylic acid, glyceryl behenate, glyceryl palmitostearate, sodium benzoate, sodium acetate, fumaric acid, zinc stearate, zinc oleate, zinc palmitate, paraffins, fatty alcohols or their mixtures can be used.

The term "glidant" in the invention; Tablet pressing immediately allows the flow of material into the matrix space. It is expressed as a substance with extra small particles and low density that facilitates it.

As a glidant; talc, magnesium stearate, hydrogenated vegetable oil, calcium stearate, stearic acid, colloidal silicon dioxide, sodium stearylfumate, polyoxyethyleneglycol, leucine, sodium benzoate, sodium chloride, sodium acetate, sodium fumarate, silica, colloidal anhydrous silica, polyethyleneglycol, cellulose derivatives, starch or their mixtures can be used.

The term "diluent" in the invention; practical, patient for the production of tablets or capsules as a substance or a mixture of substances used to be in a suitable size for its use is expressed. As a diluent; lactose, maltose, sucrose, dextrin, maiiiiitol, lactylol, xylitol, sorbitol, isomalt, microcrystalline cellulose, dextrose, dextrate, pregelatinized starch, modified starch, corn starch, lactose anhydrous, lactose monohydrate, dibasic calcium phosphate, hydroxy propyl methylcellulose, tribasic calcium phosphate, polyhydric alcohols or cellulose ethers, calcium hydrogen phosphate dihydrate, calcium sulfate trihydrate, calcium sulfate dihydrate, maltodextrin, calcium carbonate, kaolin, sodium hydroxide or their mixes can be used.

The term "preservative" in the invention; water and water-soluble, oil and fat-soluble substances It is expressed as substances that provide protection against microorganisms.

2-phenoxyethanol, sodium benzoate, beisoic acid, benzyl alcohol as preservatives, ethylenediaminetetraacetic acid, sodium methyl parahydroxy benzoate, sodium propyl para hydroxy benzoate, sorbic acid, potassium sorbate, benzetonium chloride, chlorocresol, benzalkonium chloride, butyl paraben, methyl paraben, propyl paraben, ethyl paraben, butyl hydroxy anisole (BHA), butyl hydroxy toluene (BHT), calcium acetate, citric acid, disodium edetate, glycerin, propyl gallate, sodium bisulfite, sodium citrate, sodium metabisulfite, boric acid, sorbic acid, sodium propionate, propylene glycol or their mixtures can be used.

In the invention, the term "flavoring agent" is defined as substances used to add flavoring to the mixture. is being done. As a flavoring agent; natural aroma oils (peppermint oil, wintergreen oil, parsley oil, orange oil, grape, citrus, grapefruit, lemon oil, etc.), orange flavor, banana flavor, peach flavor, grapefruit flavor, lemon flavor, apple flavor, strawberry flavor, vanilla flavor, mint flavor, tutti-furitti flavor, raspberry aroma, menthol, menthane, anethole, cinnamon, methyl salicylate, eucalyptal, sage, blackberry, citrus fruits or mixtures of these can be used.

As a "flavoring agent" in the invention; sodium saccharin, sucrose, D-glucose, galactose, xylose, maltose, maltodextrin, maltol, erythritol, lactitol, isomalt, isomaltol, corn syrup, D- tryptophan, glycyrrhizic acid, monoammonium glycyrrhizinate, fructose, maltitol, dextrose, sucrose, xylitol, sorbitol, mannitol, lactose, aspartame, acesulfame potassium, neohesperidin dihydrochalcone, sucralose, sodium cyclamate or their mixtures can be used.

In the invention, the term "viscosity increasing agent" means that it increases the thickness of the liquid and causes it to flow slowly. It is expressed as an agent or agent mixtures that provide Viscosity increasing agent aspect; xanthan gum, guar gum, acacia, povidone, alginic acid, ethylcellulose, gelatin, hydroxyethyl cellulose, hydroxypropyl cellulose, cetyl alcohol, polyvinyl pyrrolidone, hydroxy propyl methyl cellulose, polydextrose, carrageenan, methyl cellulose, sucrose, sorbitol, xylitol, hydroxypropyl methylcellulose, polyvinyl alcohol, ketaryl alcohol, colloidal silicon dioxide or mixtures of these can be used.

In the invention, the term "antifoaming agent" refers to the initiation of the foaming reaction while the product is stored. as substances that stabilize the product against the water in the existing system by preventing is expressed. As antifoaming agent; simethicone emulsion, dimethylsiloxane, silicone oil, monosodium carbonate, anhydrous trimagnesium dicitrate or mixtures thereof can be used. Antifoaming agent directly into effervescent granulated or external phase tablet It can be mixed with other excipients in powder form or made into both effervescent granules and tablets. It can be added to the excipient mixture by portioning.

As a solubilizing agent in the invention; sodium caseinate, polysorbate, methacrylic acid copolymer or mixtures thereof can be used.

The term "antistatic agent" in the invention; to reduce or eliminate static electricity in the content It is expressed as the substance or substance mixture used. The aforementioned antistatic as an agent; long Chain aliphatic amines and amides, quaternary ammonium salts, phosphoric acid esters, polyethylene glycol esters, polyols, mono and diglyceride, fatty acid esters or mixtures of these can be used.

In the invention, the term "wetting agent" is readily available in the dispersion medium of hydrophobic drugs. It is expressed as substances used to help dispersal. slacker as substance; sodium lauryl sulfate, sodium docusate, polysorbates, sorbitan monolaurate, octoxynol-9, nonoxynol-IO, poloxainers, sodium carboxymethyl cellulose, bentonite, benzalkonium chloride, tetradecyltrimethyl ammonium bromide, cetylpyridinium chloride, glyceryl monostearate, macrogol cetostearyl ether, sorbitan tristearate, aluminum magnesium silicate or mixtures of these can be used.

In the invention, the term "pH adjusting ingredient" is used to regulate the acidity and basicity of the composition. referred to as items. As a pH adjusting agent; citric acid anhydrous, sodium citrate dihydrate, sodium phosphate, sodium dihydrogen phosphate, potassium citrate, phosphoric acid, ainonian hydroxide, citric acid, diisopropanolamine, sodium carbonate, sodium silicate, disodium orthophosphate, calcium carbonate, magnesium carbonate, magnesium hydroxide, magnesium aluminate, diethanol amine, sodium alginate, ethylenediamine, meglumine, hydrochloric acid, lactic acid, sodium citrate, sodium hydroxide, sodium chloride, triethanolamine, trolamine, sodium benzoate, sodium hydrogen carbonate or their mixtures can be used.

In the invention, the term "coloring agent" is a pleasant-looking and intermediate between the two formulations. They are expressed as substances that provide optical discrimination. Colorant as substances, but not limited to, yellow iron oxide, red iron oxide such as iron oxide pigments, ß-carotene, red beet powder, chlorophyll, taitrazine, yellow orange, quinoline yellow, erythrosine, titanium dioxide pigments, caramel, sunset yellow or mixtures of these can be used.

In the invention, the term "coating agent" describes the formulation content by moisture in the air. to protect against degradation and to facilitate swallowing unpleasant-tasting forms. It is expressed as the substance or substance mixture used. Coating agent aspect; methyl cellulose, hydroxyethylcellulose, hydroxybutylcellulose, hydroxypropylmethylcellulose, ethyl cellulose, hydroxymethyl cellulose, hydroxypropylcellulose, carboxymethylethylcellulose, sodium carboxymethyl amylopectin, polyvinyl acetate phthalate, polyoxyethylene glycol, polyvinyl alcohol (opadry varieties), polyvinyl acetal diethyl aminoacetate, aminoalkyl methacrylate copolymer, methacrylic acid copolymer, hydroxypropyl methyl cellulose acetate, dioxy methyl cellulose succinate, carboxy methyl ethyl cellulose, polyacrylic acids, methacrylic acid copolymers, methyl acrylate, ethylacrylate, methylmethacrylate, ethylmethacrylate, acrylic and methacrylic acid esters, hypromellose, hypromellose phthalate, hypromellose acetate succinate, hydroxymethyl cellulose succinate acetate, cellulose butyrate phthalate, cellulose hydrogen phthalate, cellulose propyanate phthalate, cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, cellulose acetate trimellitate, gelatin, celak, castor oil, chitosan, alginic acid, carrageenan, galactomanones, tragacanth, castor oil, gum arabic, guar gum, xanthan gum or their mixtures can be used. Such as purified water, ethyl alcohol, methyl alcohol, isopropyl alcohol, butyl alcohol as a solvent. alcohols, acetone, diacetone, polyols, polyethers, esters, alkyl ketones, methylene chloride, methyl acetate, ethyl acetate, isopropyl acetate, castor oil, ethylene glycol monoethyl ether, diethylene glycol inonobutyl ether, diethylene glycol monoethyl ether, dimethyl sulfoxide, dimethyl formamide, tetrahydrofuran or mixtures thereof may be used.

The term "softening agent" in the invention; water by forming a thin film on the skin It is expressed as substances that prevent it from flying. Vaseline as an emollient, solid petrolatum, LVl paraffin, sorbitol, glycerine, hydrocarbons, lanolin, waxes, fatty acids, cetyl alcohol, octyldodecanol, caprylic/capric triglyceride, cetyl stearyl alcohol, cocoa butter, diisopropyl adipate, glycerine, polyhydric alcohols and polyether derivatives, polyhydric alcohol esters, glyceryl monooleate, glyceryl stearate, linoleic acid, oleic acid, polypropylene glycol-1S stearyl ether (PPG-1S stearyl ether), polyethylene glycol, polyoxyethylene glycol fatty alcohol ethers, polyoxypropylene stearyl ether, propylene glycol stearate, stearic acid, stearyl alcohol, phospholipids, lecithin, steorols, cholesterol, cholesterol fatty acid esters and amides, urea, glyceryl monostearate, isopropyl myristate, isopropyl palmitate, ketostearyl alcohol, diinethicone, mineral oils, white solid paraffin, cetearyl alcohol or their mixtures can be used. Moreover herbal emollient such as castor oil, coconut oil, olive oil and vegetable waxes agents can also be used.

In the invention, the term "emulsifier" means homogeneous between two immiscible liquid phases. are expressed as substances that provide dispersion. Polyethylene glycol as emulsifier stearate, polysorbate, polyglycerin] oleate, polyoxyethylene laurii ether, ethoxylated lanolin, stearyl alcohol, cetostearyl alcohol, macrogol cetostearyl, glyceryl nioiiostearate, cetostearyl alcohol, polyoxyethylene laurii alcohol, polyoxy ethylene sorbitan monostearate, polyoxyethylene stearate, sorbitan monostearate, propylene glycol stearate, aluminum starch octenylsuccinate, ammonium hydroxide, a white wax, a synthetic wax, carbomer, cetearyl alcohol, cyclomethicone, diglycerides, dimethicone, disodium monooleamido sulfosuccinate, pentaerythritol, glycerides, glyceryl monooleate, glyceryl stearate, lanolin, hydrogenated magnesium stearate, mineral oil, monoglycerides, polyethylene glycol, polyethylene glycol distearate, polyethylene glycol monocetyl ether, polyethylene glycol monostearate, polyoxyethylene glycol, polyoxyl cetostearyl ether, polyoxyl stearate, simethicone, sorbitaii monolaurate, sorbitan moiiooleate, sorbitan monopalmitate, sorbitan palmitate, stearic acid, triethanolamine or sodium lauryl sulfates or their mixtures can be used.

Propylene glycol, purified water, castor oil, diisopropyl adipate, ethoxylated alcohol, fatty alcohol citrate, glycerine, hexylene glycol, isopropyl alcohol, isopropyl myristate, isopropyl palmitate, mineral oil, phosphoric acid, polyethylene terephthalate glycol, polyethylene glycol, polyethylene glycol monostearate, polyoxyl ketostearyl ether, polyoxypropylene stearyl ether, polysorbate, octyldodecanol, propylene carbonate, saturated fatty acid triglycerides, benzoic acid, ethanol or mixtures thereof may be used.

In the invention, the term "permeabilizing agent" refers to a substance that facilitates the penetration of saliva and thus creating a hydrophilic network that contributes to better dispersion of the tablet. referred to as items. Precipitated silicas as permeation agent, maltodextrins, ß-cyclodextrins or mixtures thereof may be used.

In the invention, the term “antioxidant” prevents oxidation caused by free radicals, are substances that have the ability to capture and stabilize free radicals. is being done. As antioxidant; tocopherol (Vitamin E), ascorbic acid (vitamin C), A Vitamins such as vitamin K, carotenoids, carotenes (eg d-carotene, ß- carotene, lycopene, lutein, zeaxanthin), minerals (Se, Zn), butyl hydroxy anisole (BHA), butyl hydroxy toluene (BHT), ethylgalate, propylgalate, dodecylgalate, taurine, organosulfur compounds (allium, allyl sulfide, indoles), low molecular weight antioxidants (GSH-Px, uric acid) or mixtures of these can be used.

EDTA (ethylene diamine tetraacetic acid), disodium EDTA as chelating agent in the invention (disodium ethylene diamine tetraacetic acid) or calcium EDTA (calcium ethylene diamine) tetraacetic acid) or mixtures thereof can be used.

As an alkalizing agent in the invention; sodium carbonate, sodium hydrogen carbonate, sodium hydroxide, sodium silicate, primary amines, secondary amines, tertiary amines, cyclic amines, calcium glycerophosphate, calcium gluconate, calcium acetate, N,N, dibenzylethylenediamine, diethanolamine, ethylenediamine, meglumine, disodyuin hydrogen orthophosphate, sodium aluminate, calcium carbonate, calcium hydroxide, magnesium carbonate, magnesium hydroxide, magnesium sulfate, monosodium glutamate, polakrillin sodium, sodium alginate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulfate, magnesium acetate, magnesium silicate, magnesium aluminate, magnesium oxide or mixtures of these can be used.

As a photoprotective agent in the invention; iron oxide derivatives, metal oxides, titanium oxide or mixtures of these can be used.

In the invention, the term "thickening agent" refers to the resistance of formulations to various pressures and forces. are expressed as substances used for strengthening. thickening agent aspect; cetyl alcohol, aluminum stearate, dimethicone, cetearyl alcohol, stearyl alcohol, gum arabic, gum tragacanth, alginate, carrageenan, xanthan gum, guar gum, cetostearyl alcohol, cetyl esters inuinu, dextrin, glyceryl monostearate, hydroxypropyl cellulose, kaolin, polyethylene white petrolatum, propylene glycol stearate, starch, wax, white wax, bentonite, beeswax, white beeswax, synthetic wax, paraffin, white solid paraffin, white soft paraffin, solid Vaseline, pectin, carbomer, polyvinylpyrrolidone or their mixtures can be used.

In the invention, the term "isotonia adjusting agent" means the same osmotic pressure as the standard reference substance. referred to as substances. As the aforementioned isotonia adjusting agent; sodium chloride, mannitol, sorbitol, boric acid, potassium nitrate, glucose or their mixes can be used.

In the invention, carbopol, carbomer, hydroxy propylmethylcellulose, methylcellulose, sodium carboxymethylcellulose, polyacrylate polymers or their mixes can be used.

In the invention, the term "microbial preservative" protects against microbial activity. referred to as items. As the aforementioned microbial preservative; sodium benzoate, sodium inethyl para hydroxybenzoate, sodium propyl para hydroxybenzoate, benzalkonium chloride, boric acid, sorbic acid, ethanol or their mixtures can be used.

In the invention, “hardening agent; The term means formulations against various pressures and forces. are expressed as substances used for strengthening. As a hardening agent; cetyl alcohol, aluminum stearate, dimethicone, cetearyl alcohol, stearyl alcohol, gum arabic, tragacanth gum, alginate, carrageenan, xanthan gum, guar gum, cetostearyl alcohol, cetyl esters wax, dextrin, glyceryl monostearate, hydroxypropyl cellulose, kaolin, polyethylene white petrolatum, propylene glycol stearate, starch, wax, white wax, bentonite, beeswax, white beeswax, synthetic wax, paraffin, white solid paraffin, solid petrolatum, pectin, carbomer, polyvinylpyrrolidone or mixtures thereof can be used.

As Sivag in the invention; macrogol derivatives, petrolatum, wax modified vaseline, liquid petrolatum, white petrolatum, laiioliii or lanolin derivatives, castor oil, coconut oil, olive oil, vegetable oils such as cottonseed oil, polyethylene glycol, paraffin, anhydrous, white soft paraffin or their mixtures can be used.

As "release controlling agent" in the invention; polyvinyl acetate phthalate, polyethylene glycol-polyvinyl alcohol copolymer, polyacrylic acid derivatives, polysaccharide derivatives, methacrylate polyiner, polymethacrylate, ethyl inethacrylate copolymer, methacrylic acid-methylinethacrylate copolymer, methacrylic acid-ethyl acrylate copolymer, polylactic acid, polylactic acid copolymer, polyviiylpyrrolidone, polyvinylalcohol, glyceride, polyethylene oxide, glyceryl behenate, methacrylic acid copolymer, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose acetate, carboxy methyl ethyl cellulose, sodium carboxy methyl cellulose, ethyl cellulose, methyl acrylate, ethylacrylate, methylmethacrylate, ethylmethacrylate, acrylic and methacrylic acid esters, sodium alginate, hypromellose phthalate, hypromellose acetate succinate, cellulose butyrate phthalate, cellulose hydrogen phthalate, cellulose propyanate phthalate, cellulose acetate phthalate, cellulose acetate Trimelitate, gelatin, celak, xanthan gum or mixtures of these can be used.

In the invention, the term "plasticizer" is used to increase the flexibility of the coating, reduce the risk of film breakage. It is expressed as substances used to reduce the film and increase the adhesion of the film to the core. is being done. They must be compatible with the polymer and not be volatile.

As a plasticizer; polyethylene glycols (Macrogol), glycerin, propylene glycol, acetyl citrate, amyl oleate, myristyl acetate, butyl oleate, butyl stearate, triacetin, diethylphthalate, acetylated monoglycerides or mixtures thereof may be used.

In the invention, the term "antiadherent" refers to substances that prevent the formation of a rough tablet surface. is expressed. As an antiadherent; talc, colloidal silicon dioxide (Aerosil, Syloid, Cab-O-Sil), magnesium stearate, corn starch, magnesium trisilicate or their mixes can be used.

In the invention, the term "film-forming agent" refers to the use of a binder as a film, eg film or substrate. It is expressed as the necessary components to create it. As a film making agent; polyvinyl alcohol-partially hydrolyzed, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, polyethylene glycol, polyethylene oxide, Macrogol, gelatin or their mixtures can be used.

In the invention, the term "opacifying agent" refers to the addition of the desired system to make it opaque. referred to as items. As an opacifying agent; titanium dioxide, calcium carbonate, zinc acetate, aluminum stearate, zinc stearate or mixtures thereof can be used.

The term "moisturizing agent" in the invention; the amount of moisture between the preparation and the air. are expressed as substances that regulate and control. Humidifier aspect; glycerin, sorbitol, propylene glycol, urea, colloidal ingredients, liquid paraffin, petrolatum (petrolatum), liquid petrolatum, cellulose and cellulose-containing substances, gums (tragacanth), some electrolytes (Al salts, mercury salts borax) or their mixtures can be used.

Purified water, ethyl alcohol, methyl alcohol, isopropyl as granulation solvent in the invention Alcohols such as alcohol, butyl alcohol, methylene chloride or their mixtures can be used.

In the invention, the term "suspension agent" is used to increase viscosity and slow settling. used for the purpose. As a "suspension agent" in the invention, xanthan gum, guar gum, carrageenan, ethylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, hydroxypropyl methylcellulose (HPMC), methyl cellulose or mixtures thereof can be used.

The term "stabilizer" in the invention; prevents crystallization or phase separation when added referred to as items. Benzoic acid, edetic acid, salicylic acid as stabilizer, sorbic acid, sodium dehydroacetate, tocopherol, butylated hydroxyanisole, butylated hydroxytoluene, propylgallate, castor oil, oleyl alcohol, poloxamer and poloxamines (polyoxyethylene and polyoxypropylene block copolymer), xanthan gum, sorbitan oil ethoxylated esters of acids, polysorbates such as polysorbate 80 or Tween 80, ethoxylated mono- and diglycerides, ethoxylated lipids, ethoxylated fatty alcohols or fatty acids, diacetyl phosphate, phosphatidyl glycerol, saturated or unsaturated fatty acids, sodium cholate, sodium glycolate, sodium taurocholate, paraoxybenzoic acid, ethylene diamine tetraacetic acid (EDTA), diethylene triamine penta acetic acid or mixtures thereof can be used.

Appropriate active ingredient(s) and/or pharmaceutically acceptable in the present invention Ambroxol in pharmaceutical composition containing derivatives and/or pharmaceutically acceptable the amount of derivatives available is 5-750mg, preferably 1Smg and 30mg; Paracetamol and/or The amount of pharmaceutically acceptable derivatives is 10-1200mg, preferably 50mg, 80mg, 100mg, 1SOmg, 1SOmg, 240mg, SOOing; Pseudoephedrine and/or pharmaceutically acceptable adjusted according to individual needs and expert assessment.

The invention mainly consists of a suitable active substance and/or mucolytic agent for oral use. pharmaceutically acceptable derivatives with analgesic and/or antipyretic properties appropriate active ingredient and/or pharmaceutically acceptable derivatives and sympathomimetic With the appropriate active ingredient and/or pharmaceutically acceptable derivatives combination therapy and suitable pharmaceutically acceptable excipients. relates to the preparation of pharmaceutical composition(s). Thus, the prepared Ainbroxol and/or Paracetamol and/or pharmaceutically acceptable derivatives acceptable derivatives and acceptable as pseudoephedrine and/or pharmaceutical formulation/s containing the combination with its derivatives are combined synergistically. antibacterial resistance of pharmaceutical formulations with the breaking of bacterial resistance its activity and thus its therapeutic efficacy has been increased and surprisingly, its physical and It was observed that they exhibited a very stable behavior in terms of chemical stability.

Claims (1)

REQUESTS For oral use, suitable active substance and/or pharmaceutically acceptable derivatives with mucolytic properties, suitable active substance and/or pharmaceutically acceptable derivatives with analgesic and/or antipyretic properties and suitable active substance and/or pharmaceutically acceptable derivatives with sympathomimetic properties Preparation of pharmaceutical composition(s) containing the combination therapy and suitable pharmaceutically acceptable excipients. It is a pharmaceutical composition/s as in claim 1 and its feature is; the appropriate active ingredient with mucolytic properties is selected among erdosteine, acetylcysteine, ambroxol, bromhexine, carbocysteine, domiodol, eprazinone, letostein, neltenexin, sobrerol, steproniii, thiopronin and/or pharmaceutically acceptable derivatives. It is pharmaceutical composition/s as in Claim 1 and its feature is; A suitable active ingredient with mucolytic properties is preferably ambroxol hydrochloride. It is a pharmaceutical composition/s as in claim 1 and its feature is; Acetylsalicylic acid, aloxiprine, choline salicylate, sodium salicylate, salicyl salsalate, ethenzamide, morpholine salicylate, dipyrocetyl, benorilate, diflunisal, potassium salicylate, guacetisal, carbasalate calcium, imidazole aminophenacisylate, , propyphenazone, niphenazone, paracetamol, phenacetin, busetin, propacetamol, rinazolium, glafeiin, floctafenin, viminol, iiefopam, flupirtine, ziconotide, methoxyflurane, nabiximols, morphine, opium, hydromorphone, nicomorphine, diomorphine, diomorphine, ketomidone, hydromorphone, nicomorphine, diaphragm , fentanyl, dextromoramide, pyrithramide, dextropropoxyphene, beztramide, pentazocine, phenazosine, buprenorphine, butorphanol, nalbuphine, tilidiii, tramadol, dezosine, meptazinol, tapeitadol, dihydroergotainin, ergotanin, metyrgotanone, narcisstriptanone , eletriptan, frovatriptan, pizotifen, clonidine, iprazochrome, dimethothiazine , oxetorone, zucapsaicin and/or pharmaceutically acceptable derivatives. It is a pharmaceutical composition/s as in the request, and its feature is; The appropriate active ingredient with analgesic and/or antipyretic properties is preferably paracetamol. It is a pharmaceutical composition/s as in Claim 1 and its feature is; It is the selection of the appropriate active ingredient with sympathomimetic properties among phenylpropanolamine, pseudoephedrine, phenylephrine, phenylpropylamine and/or pharmaceutically acceptable derivatives. It is a pharmaceutical composition/s as in the request, and its feature is; The appropriate active ingredient with sympathomimetic properties is preferably pseudoephedrine hydrochloride. It is a pharmaceutical composition/s as in claim 11 and its feature is; tablet of pharmaceutical dosage form (uncoated, chewable, orally soluble, dispersible, water-dispersible, film-coated, monolayer, bilayer, intestinal release coated, mini tablet, controlled release, sustained release, immediate release, extended release, delayed release, modified release, buccal), capsule (hard, soft, enteric coated, film coated, controlled release, sustained release, immediate release, extended release, delayed release, modified release), powder, dry powder, granule, caplet, disc, oral soluble film , bulk powder (multidose), pellet, sachet, water-dispersible powder, water-dispersible granule, effervescent tablet, effervescent granule, effervescent powder, microcapsule, dental tablets, pilula, syrup, solution, suspension, elixir, drops, position, emulsion or comprising one or more pharmaceutical dosage forms selected from sprays. It is a pharmaceutical composition/s according to any of the above claims and its feature is; 5-750mg of the amount of Ambroxol and/or pharmaceutically acceptable derivatives in the pharmaceutical composition containing the appropriate active ingredient/s and/or pharmaceutically acceptable derivatives; 10-1200mg of the amount of paracetamol and/or its pharmaceutically acceptable derivatives; The amount of pseudoephedrine and/or pharmaceutically acceptable derivatives is 0.1-800 mg. It is a pharmaceutical composition/s according to any of the above claims and its feature is; Prophylactic and/or symptomatic and/or treatment of chronic respiratory system diseases such as colds, chronic obstructive pulmonary disease (COPD), pulmonary diseases such as emphysema and bronchospasm, cough, expectoration, middle ear inflammation, chronic asthma, chronic bronchitis, bronchial asthma, bronchiectasis is indicated for therapeutic treatment.